Topic 02 / 07

Regulation in Japan

Japan regulates regenerative medicine under the Act on the Safety of Regenerative Medicine. This topic covers the legal framework, the risk classes, provision plans and review committees, and recent amendments.

01What this topic covers

  • The Act on the Safety of Regenerative Medicine
  • Class I, Class II and Class III
  • Provision plans and review committees
  • The 2025 amendment
  • The MHLW information and reporting window

02Three things to know first

  • November 2014: Japan’s Act on the Safety of Regenerative Medicine took effect.
  • Before treatment, a medical institution must prepare a “provision plan for regenerative medicine”, have it reviewed by a certified committee and submit it to the MHLW; offering treatment without doing so is illegal.
  • Three classes: Class I (high risk), Class II (medium risk), Class III (low risk).

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11 · Read the full regulation guide

03Guides in this topic

Guides are on the way

Guides for this topic are being prepared, each with its sources and the date it was checked. Meanwhile, start with these pages.

04Other topics

The information on this site is general information and is not medical advice; whether any therapy suits you can only be decided by a doctor after an in-person consultation.
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk.

Chat with an advisor